¡Ya estamos en !
Descubre más
ICPT
Intercept Pharmaceuticals, Inc.
Excluida de cotización
ICPT dejó de cotizar en bolsa el 7 de noviembre de 2023.
Acerca de: Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Empleados: 341
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
No hemos recibido artículos de noticias recientes sobre ICPT.
Gráficos de precios implementados con Lightweight Charts™